Millenco boosts stake in ArQule

By Lisa Kerner

Charlotte, N.C., Aug. 30 - Investors led by Millenco, LLC purchased 777,655 shares of ArQule, Inc. stock between Aug. 1 and Aug. 29 priced from to $5.57 to $8.24.

The transactions were reported in a schedule 13D filing with the Securities and Exchange Commission.

Millenco and the reporting persons own 3,025,100 shares, or 6.9%, of the company's outstanding stock.

Based in Woburn, Mass., ArQule is a biotechnology company focused on cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.